Lb Pharmaceuticals (LBRX) Income towards Parent Company (2024 - 2026)

Lb Pharmaceuticals has reported Income towards Parent Company for 3 years, with the latest figure at -$19.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 259.1% year-over-year to -$19.1 million; the trailing twelve-month figure through Mar 2026 stood at -$39.4 million (changed N/A YoY), and the FY2025 full-year result was -$25.2 million, up 60.06% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$19.1 million, down from -$11.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$3.6 million in Q3 2025, with the low at -$19.1 million in Q1 2026.
• Average Income towards Parent Company over 3 years is -$9.8 million, with a median of -$8.4 million recorded in 2025.
• Year-over-year, Income towards Parent Company soared 74.92% in 2025 and slumped 259.1% in 2026.
• Tracing LBRX's Income towards Parent Company over 3 years: stood at -$5.1 million in 2024, then tumbled by 126.23% to -$11.5 million in 2025, then slumped by 66.09% to -$19.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$19.1 million (Q1 2026), -$11.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.

Peer Comparison